

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VENTUREPHARM LABORATORIES LIMITED

萬全科技藥業有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code:8225)

POSTPONEMENT OF BOARD MEETING, DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND DESPATCH OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2010

The Board of Venturepharm Laboratories Limited (the“Company”) announces that the Board Meeting to consider the annual results of the Group for the year ended December 31, 2010 which was originally scheduled to be held on March 30, 2011, will be postponed to be held on March 31, 2011, as a result of the new appointment of auditor and inappropriate arrangement of auditing schedule. Accordingly, there will be a delay in the publication of the annual results announcement and the despatch of the annual report for the Year 2010, and could be expected to fulfill on March 31, 2011.

By order of the Board
Venturepharm Laboratories Limited
William Xia Guo
Chairman

Beijing, the PRC, 31 March 30, 2011

** For identification purpose only*

As at the date of this announcement, the Board comprises two executive directors, being Mr. William Xia Guo and Dr. Maria Xue Mei Song; three non-executive directors, being Mr. Feng Tao, Mr. Wu Xin and Dr. Nathan Xin

Zhang; and three independent non-executive directors, being Mr. Wang Hong Bo, Mr. Paul Contomichalos and Mr. Wu Ming Yu.

This announcement, for which the directors of the Company (the “Directors”) collectively and individually accept responsibility, includes particulars given in compliance with the Rules Governing the Listing of securities of the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, conform that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respect and not misleading; (2) there are no other matters the omission of which would make any statement in all material respects and not misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website with the domain name of www.hkgem.com on the “Latest Company Announcements” page for at least 7days from the date of its posting and on the Company’s website at www.venturepharm.com